Generic injectable lenacapavir: what the FDA approval means for US PrEP programs
On November 2, 2026, the FDA granted tentative approval to Dr. Reddy's Laboratories for the first generic version of twice-yearly injectable lenacapavir for HIV PrEP. It is meant for 120 low- and middle-income countries, not the US market. For US programs, the brand-name product and its HIV testing requirements stay the same.
That is the short version. The longer version matters if you run a PrEP telehealth service, a sexual health clinic or a lab program, because the headline "FDA approves generic HIV prevention shot" is easy to misread. Here is what happened, what it does and doesn't change in the US, and why long-acting PrEP still runs on lab work.
This article is general information for program operators, not medical advice.
What the FDA actually approved
According to Dr. Reddy's announcement, the FDA granted tentative approval to its long-acting injectable lenacapavir for PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents who weigh at least 35 kg (77 lb). The approval came under the FDA's program for the President's Emergency Plan for AIDS Relief (PEPFAR).
The key facts from the announcement and from Unitaid, which supported the work with Wits RHI and the Clinton Health Access Initiative (CHAI):
Timing: it came about 16 months after the FDA approved Gilead's originator product for HIV prevention in June 2025.
Price: under an agreement announced in September 2025, the generic will be available at US$40 per person per year in the 120 countries covered by Gilead's voluntary license.
Supply: first supplies are expected to reach countries before the end of 2026, with broader availability in 2027.
Next steps: Dr. Reddy's says WHO prequalification and national regulatory approvals are still part of the path to wider availability.
Unitaid also reports that more than 125,000 people in 10 early adopter African countries had already started Gilead's lenacapavir before any generic was available.
What "tentative approval" means
Tentative approval is not the same as a US launch. Unitaid describes it as the FDA's standard designation for generics while the originator product is still under patent, and notes that it enables procurement by the US government. AP reports that the generic can't be sold in the US because Gilead's brand-name version, Yeztugo, is still protected by a patent.
So for US programs, the practical reading is:
Yeztugo remains the lenacapavir PrEP product in the US market.
The $40 price applies to the 120 countries in the voluntary license, not to US patients, payers or employers.
Nothing in this news changes US prescribing, coverage or dosing rules.
If a patient or partner asks whether a cheap generic shot is coming to US pharmacies soon, the accurate answer, based on these sources, is no.
Why the news still matters to US programs
Even without a US launch, the approval signals a few things worth tracking:
Long-acting PrEP is going mainstream globally. PrEPWatch tracks approvals and rollout country by country and notes that injectable lenacapavir is recommended and prequalified by WHO.
The pipeline is busy. PrEPWatch lists a once-yearly lenacapavir formulation in a Phase III trial and a weekly oral lenacapavir pill under FDA review, with a decision expected in February 2027.
Patients will hear about it. Headlines about a twice-yearly shot raise interest, and programs should be ready to explain options clearly and accurately.
For operators, more interest in long-acting PrEP means more patients on testing schedules that are tied to injection visits.
Long-acting PrEP still depends on HIV testing
A shot every six months removes the daily pill. It does not remove the lab work. The Yeztugo prescribing information says individuals must be screened for HIV-1 before starting, before each injection and additionally as clinically appropriate, using a test approved or cleared by the FDA for diagnosing acute or primary HIV-1 infection.
The label adds a few specifics programs should build into their workflow:
At initiation: if an antigen/antibody test is negative, confirm it with an RNA assay, even if the RNA result comes back after the first dose.
Before each later injection: a negative rapid point-of-care antigen/antibody result should be confirmed with a more sensitive assay.
Between injections: test again when clinically appropriate, for example after another STI diagnosis or symptoms that could suggest acute HIV.
Why so strict? The label explains that lenacapavir alone is not a complete HIV treatment regimen. If someone has undiagnosed HIV and keeps receiving it, resistance can develop. Testing before every dose is the safeguard.
Missed visits and stopping
Two more points from the label affect scheduling:
People who miss a scheduled injection visit should be clinically reassessed, including confirming they are still HIV-negative.
Because the drug is long-acting, the label says other forms of PrEP should be considered for people who stop and remain at risk, started within 28 weeks of the last injection.
Both of these create lab touchpoints outside the six-month rhythm. A program that only plans for two tests a year will miss them.
STI screening doesn't go away
Lenacapavir prevents HIV only. PrEPWatch notes it does not prevent other sexually transmitted infections, and the label counsels routine testing for HIV-1 and other STIs.
CDC's clinical guidance for PrEP recommends screening for chlamydia, gonorrhea and syphilis for all sexually active adults before starting oral or injectable PrEP, with ongoing STI screening while on PrEP. That page, last updated in April 2026, gives detailed injectable schedules for cabotegravir. For lenacapavir, the product label sets the HIV testing rules, and clinical teams decide the STI cadence.
CDC also says that for PrEP delivered by telehealth, lab-only visits for HIV testing are strongly preferred, and it advises against oral swab self-tests for PrEP patients except when no lab or clinic visit is possible.
A short readiness checklist for US programs
If your service offers or plans to offer long-acting PrEP, these are the lab questions to settle now:
Can every injection visit be paired with an HIV test that meets the label, timed so results are available when the clinician needs them?
Is there a clear path to RNA confirmation at initiation and to a more sensitive confirmatory assay when a rapid test is used?
How will you catch missed visits and patients stopping, so testing continues through the window after the last dose?
Do STI screening orders (including multi-site testing where clinically indicated) line up with injection visits?
Who reviews results and acts on a reactive HIV or positive STI result, and how fast?
Our PrEP lab-monitoring checklist compares oral and injectable schedules side by side if you want a deeper planning tool.
Where the lab fits
Labs don't prescribe PrEP. Their job is to make the required testing reliable, fast and easy to schedule around injection visits. IHDLab is a CLIA-certified lab (05D2040304) licensed in California, New York and Maryland that works with telehealth and clinic programs on HIV and STI testing. Patient service centers and courier pickup are available in California only.
The bottom line
The generic lenacapavir approval is a major step for global HIV prevention, with a US$40 annual price for 120 low- and middle-income countries and first supplies expected by the end of 2026. It does not bring a generic to the US market while the originator is under patent. For US programs, the takeaway is operational: twice-yearly PrEP still means an HIV test before every injection, ongoing STI screening and a plan for missed visits.
If you are mapping that testing workflow, our PrEP and STI lab testing page outlines what we support.
